Patents by Inventor Hye Nan Kim
Hye Nan Kim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11248048Abstract: Disclosed are an antibody to human programmed cell death 1 (PD-1) or an antigen-binding fragment thereof, a nucleic acid encoding the same, a vector including the nucleic acid, an isolated cell transformed with the vector, a method for producing the antibody or an antigen-binding fragment thereof, and a composition for preventing or treating cancer containing the same. The novel antibody binding to PD-1 or an antigen-binding fragment thereof can bind to PD-1 and inhibit the activity of PD-1, thus being useful for the development of immunotherapeutic agents for various diseases associated with PD-1.Type: GrantFiled: August 7, 2017Date of Patent: February 15, 2022Assignee: Y-BIOLOGICS INC.Inventors: Jae Eun Park, Soo Young Kim, Hyun Mi Lee, Si Hyung Lee, Hyun Kyung Lee, Hye-Nan Kim, Jin Chui Youn, Bum-chan Park, Jung Chae Lim, Young-Gyu Cho, Young Woo Park
-
Publication number: 20190248900Abstract: Disclosed are an antibody to human programmed cell death 1 (PD-1) or an antigen-binding fragment thereof, a nucleic acid encoding the same, a vector including the nucleic acid, an isolated cell transformed with the vector, a method for producing the antibody or an antigen-binding fragment thereof, and a composition for preventing or treating cancer containing the same. The novel antibody binding to PD-1 or an antigen-binding fragment thereof can bind to PD-1 and inhibit the activity of PD-1, thus being useful for the development of immunotherapeutic agents for various diseases associated with PD-1.Type: ApplicationFiled: August 7, 2017Publication date: August 15, 2019Inventors: Jae Eun Park, Soo Young Kim, Hyun Mi Lee, Si Hyung Lee, Hyun Kyung Lee, Hye-Nan Kim, Jin Chul Youn, Bum-chan Park, Jung Chae Lim, Young-Gyu Cho, Young Woo Park
-
Patent number: 10259850Abstract: Provided are a modified DKK2 polypeptide according to an aspect, a nucleic acid encoding the same, a preparation method thereof, and use thereof. Accordingly, a modified DKK2 protein having an additional glycosyl group or improved binding affinity for a substrate LRP6 may be efficiently prepared, thereby being used for promoting angiogenesis or preventing or treating vascular permeability-related diseases.Type: GrantFiled: February 3, 2016Date of Patent: April 16, 2019Assignee: MEDPACTO INC.Inventors: Il Ho Ha, Seok Ho Yoo, Hye Nan Kim, Yeung Chul Kim, Ju Ry Lim
-
Publication number: 20180016313Abstract: Provided are a modified DKK2 polypeptide according to an aspect, a nucleic acid encoding the same, a preparation method thereof, and use thereof. Accordingly, a modified DKK2 protein having an additional glycosyl group or improved binding affinity for a substrate LRP6 may be efficiently prepared, thereby being used for promoting angiogenesis or preventing or treating vascular permeability-related diseases.Type: ApplicationFiled: February 3, 2016Publication date: January 18, 2018Applicant: MEDPACTO INC.Inventors: Il Ho HA, Seok Ho YOO, Hye Nan KIM, Yeung Chul KIM, Ju Ry LIM
-
Patent number: 9631020Abstract: Disclosed are a human antibody comprising a human complementarity-determining region (CDR), which binds specifically to c-Met, and a framework region (FR), a polynucleotide encoding the human antibody, an expression vector comprising the polynucleotide, a transformant transformed with the expression vector, a method of producing the human antibody B7 by culturing the transformant, a wound healing composition comprising the human antibody as an active ingredient, a cell regeneration composition comprising the antibody as an active ingredient, and a drug conjugate comprising a drug linked to the human antibody. The c-Met-specific human antibody can function as an HGF mimic that can be used as a wound healing composition. The antibody can be widely used to determine the treatment and prognosis of various diseases, including neuronal infarction, progressive nephropathy, liver cirrhosis, lung fibrosis, kidney injury, liver injury, lung injury, and ulcerative wounds, which are treated by activation of HGF or c-Met.Type: GrantFiled: June 4, 2012Date of Patent: April 25, 2017Assignees: Korea Research Institute of Bioscience and Biotechnology, Y-Biologics Inc.Inventors: Young Woo Park, Ki Won Jo, Chan Woong Park, Seok Ho Yoo, Myeoung Hee Jang, Hye Nan Kim, Seon Ha Yun, Kyu Won Cho, Mi Ra Park
-
Patent number: 9388223Abstract: The present invention relates to a myostatin inhibitor comprising extracellular water-soluble domains of delta-like 1 homolog (DLK1) as active ingredients. More particularly, the present invention relates to a composition for inhibiting myostatin activity, comprising, as active ingredients, extracellular water-soluble domains of DLK1 or a deletion mutant of extracellular water-soluble domains of DLK1. The myostatin inhibitor of the present invention is bonded to the myostatin or activin receptor type IIB so as to inhibit the action mechanism of the myostatin, to thereby promote myogenesis and prevent differentiation into fat cells. Therefore, the myostatin inhibitor of the present invention may be used in preventing and treating diseases such as muscular dysplasia that requires differentiation to muscular cells, or metabolic diseases.Type: GrantFiled: January 3, 2013Date of Patent: July 12, 2016Assignee: Antibody and Receptor Therapeutics Co., Ltd.Inventors: Dong Hee Lee, Bum Chan Park, Jae Eun Park, Myeong Hee Jang, Seok Ho Yoo, Hye Nan Kim
-
Patent number: 9364556Abstract: The present invention relates to a drug conjugate comprising a cytotoxic drug conjugated to a c-Met specific human antibody. More specifically, the present invention relates to: a drug conjugate comprising a cytotoxic drug conjugated to a c-Met specific human antibody; a pharmaceutical composition for cancer treatment comprising the drug conjugate; and a cancer treatment method comprising a step in which the drug conjugate or pharmaceutical composition is administered to an individual.Type: GrantFiled: November 28, 2012Date of Patent: June 14, 2016Assignees: Korea Research Institute of Bioscience and Biotechnology, A&RT Co., Ltd.Inventors: Young Woo Park, Ki Won Jo, Sun Jeong Jo, Soon Sil Hyun, Jae Eun Park, Seok Ho Yoo, Myeoung Hee Jang, Hye Nan Kim, Chan Woong Park
-
Publication number: 20150110815Abstract: The present invention relates to a drug conjugate comprising a cytotoxic drug conjugated to a c-Met specific human antibody. More specifically, the present invention relates to: a drug conjugate comprising a cytotoxic drug conjugated to a c-Met specific human antibody; a pharmaceutical composition for cancer treatment comprising the drug conjugate; and a cancer treatment method comprising a step in which the drug conjugate or pharmaceutical composition is administered to an individual.Type: ApplicationFiled: November 28, 2012Publication date: April 23, 2015Applicant: Korea Research Institute of Bioscience and BiotechnologyInventors: Young Woo Park, Ki Won Jo, Sun Jeong Jo, Soon Sil Hyun, Jae Eun Park, Seok Ho Yoo, Myeoung Hee Jang, Hye Nan Kim, Chan Woong Park
-
Publication number: 20150030595Abstract: The present invention relates to a myostatin inhibitor comprising extracellular water-soluble domains of delta-like 1 homolog (DLK1) as active ingredients. More particularly, the present invention relates to a composition for inhibiting myostatin activity, comprising, as active ingredients, extracellular water-soluble domains of DLK1 or a deletion mutant of extracellular water-soluble domains of DLK1. The myostatin inhibitor of the present invention is bonded to the myostatin or activin receptor type IIB so as to inhibit the action mechanism of the myostatin, to thereby promote myogenesis and prevent differentiation into fat cells. Therefore, the myostatin inhibitor of the present invention may be used in preventing and treating diseases such as muscular dysplasia that requires differentiation to muscular cells, or metabolic diseases.Type: ApplicationFiled: January 3, 2013Publication date: January 29, 2015Inventors: Dong Hee Lee, Bum Chan Park, Jae Eun Park, Myeong Hee Jang, Seok Ho Yoo, Hye Nan Kim
-
Publication number: 20140193431Abstract: Disclosed are a human antibody comprising a human complementarity-determining region (CDR), which binds specifically to c-Met, and a framework region (FR), a polynucleotide encoding the human antibody, an expression vector comprising the polynucleotide, a transformant transformed with the expression vector, a method of producing the human antibody B7 by culturing the transformant, a wound healing composition comprising the human antibody as an active ingredient, a cell regeneration composition comprising the antibody as an active ingredient, and a drug conjugate comprising a drug linked to the human antibody. The c-Met-specific human antibody can function as an HGF mimic that can be used as a wound healing composition. The antibody can be widely used to determine the treatment and prognosis of various diseases, including neuronal infarction, progressive nephropathy, liver cirrhosis, lung fibrosis, kidney injury, liver injury, lung injury, and ulcerative wounds, which are treated by activation of HGF or c-Met.Type: ApplicationFiled: June 4, 2012Publication date: July 10, 2014Applicant: Korea Research Institute of Bioscience and BiotechnologyInventors: Young Woo Park, KiWon Jo, Chan Woong Park, Seok Ho Yoo, Myeoung Hee Jang, Hye Nan Kim, Seon Ha Yun, Kyu Won Cho, Mi Ra Park
-
Publication number: 20140072558Abstract: The present invention relates to an activin receptor type II B (ACVR2B) inhibitor which comprises the delta-like 1 homolog (DLK1) extracellular water-soluble domain. More specifically, the present invention relates to an extracellular soluble domain of DLK1; fragments of the extracellular soluble domain of DLK1; mutants of the extracellular soluble domain of DLK1; a composition for suppressing ligand linkage with the ACVR2B receptor, which includes a fragment of the mutants as an active ingredient; and a pharmaceutical composition for prevention and treatment of diseases which comprises the same. The composition of the present invention competitively binds to the ACVR2B receptor and inhibits the binding of an ACVR2B ligand to the ACVR2B receptor, which inhibits protein signalling associated with such ligands, and will be useful for prevention and treatment of diseases associated therewith.Type: ApplicationFiled: April 3, 2012Publication date: March 13, 2014Applicants: ANTIBODY AND RECEPTOR THERAPEUTICS CO., LTD., KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGYInventors: Young Woo Park, Ki Won Jo, Donghee Lee, Eun Kyung Lee, Seil Jang, Chan Woong Park, Dong-Jin Kim, Hye Nan Kim, Yun Jung Park, Jae Eun Park, Ji Hyun Park, Seok Ho Yoo, Myeoung Hee Jang
-
Patent number: 8183405Abstract: Disclosed herein are novel obovatol derivatives represented by Chemical Formula 1, and pharmaceutically acceptable salts thereof. Having the ability to inhibit the growth of cancer cells and induce apoptosis in cancer cells, the derivatives or pharmaceutically acceptable salts thereof are useful in the prevention and treatment of cancer and in the suppression of cancer metastasis. Also, a method for preparing the derivatives, and pharmaceutical compositions comprising the derivatives as active ingredients are disclosed. wherein R1, R2 and R3 are as defined in the specification.Type: GrantFiled: July 28, 2008Date of Patent: May 22, 2012Assignee: Korea Research Institute of Bioscience and BiotechnologyInventors: Byoung-Mog Kwon, Dong Cho Han, Su-Kyung Lee, Hye-Nan Kim, Young-Min Han, Dae-Seop Shin
-
Patent number: 7939542Abstract: Disclosed herein are a novel cinnamaldehyde compound represented by Chemical Formula 1 or pharmaceutically acceptable salts thereof. The cinnamaldehyde compound has improved solubility in water and has inhibitory effects on the growth of cancer cells because it induces cell cycle arrest and cell death. Also disclosed are a method of preparing the cinnamaldehyde compound and an anticancer composition including the compound of Chemical Formula 1.Type: GrantFiled: August 28, 2008Date of Patent: May 10, 2011Assignee: Korea Research Institute of Bioscience and BiotechnologyInventors: Byoung Mog Kwon, Dong Cho Han, Hye Nan Kim, Young Min Han, Dae Seop Shin, Yeong Rim Kang
-
Publication number: 20100125103Abstract: Disclosed is a pharmaceutical composition containing obovatol represented by Formula 1 and its derivatives. The obovatol and its derivatives effectively increase the activity of AMPK (AMP-activated protein kinase) that plays an important role in diabetes and metabolic syndrome, and thus may be variously used in treating diabetes and metabolic syndrome. (In Formula 1, R1, R2 and R3 are the same as defined above).Type: ApplicationFiled: June 15, 2009Publication date: May 20, 2010Applicants: TG BIOTECH CO. LTD., KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGYInventors: Tae-Lin Huh, Hebok Song, Ji-Eun Kim, Byoung-Mog Kwon, Dong Cho Han, Hye-Nan Kim
-
Publication number: 20090325972Abstract: Disclosed herein are a novel cinnamaldehyde compound represented by Chemical Formula 1 or pharmaceutically acceptable salts thereof. The cinnamaldehyde compound has improved solubility in water and has inhibitory effects on the growth of cancer cells because it induces cell cycle arrest and cell death. Also disclosed are a method of preparing the cinnamaldehyde compound and an anticancer composition including the compound of Chemical Formula 1.Type: ApplicationFiled: August 28, 2008Publication date: December 31, 2009Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGYInventors: Byoung Mog KWON, Dong Cho HAN, Hye Nan KIM, Young Min HAN, Dae Seop SHIN, Yeong Rim Kang
-
Publication number: 20090311354Abstract: The present invention relates to a composition for the prevention and treatment of inflammatory disease containing the extracts of Magnolia obovata or fractions thereof as an active ingredient, more precisely, a composition for the prevention and treatment of inflammatory disease containing the extracts of Magnolia obovata fruits and floral buds extracted with alcohol or alcohol aqueous solution as a solvent and active fractions isolated from the same. The extracts and fractions of the present invention inhibit lipopolysaccharide (LPS) induced nitric oxide (NO) generation significantly, have anti-inflammation activity and low cytotoxicity, and contain all of major effective components isolated from Magnolia obovata such as obovatol, honokiol and magnolol, so that they can be effectively used for the prevention and treatment of inflammatory disease.Type: ApplicationFiled: August 26, 2008Publication date: December 17, 2009Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGYInventors: Byoung-Mog KWON, Dong Cho HAN, Hye-Nan KIM, Young-Min HAN, So Young LEE, Dae-Seop SHIN
-
Publication number: 20090263521Abstract: The present invention relates to a composition containing the extracts of Magnolia obovata Thunberg or fractions thereof for the prevention and treatment of cancer and for the inhibition of metastasis. Particularly, the extracts of Magnolia obovata Thunberg fruits and floral buds extracted with water, alcohol or a mixture thereof as a solvent and fractions isolated from the same inhibit metastasis by inhibiting migration of those cells over-expressing PRL-3 which plays an important role in cancer cell growth and migration and at the same time induce apoptosis of cancer cells, so that they can be effectively used as a composition for the prevention and treatment of cancer or a composition for the inhibition of metastasis.Type: ApplicationFiled: August 14, 2008Publication date: October 22, 2009Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGYInventors: Byoung-Mog KWON, Dong Cho HAN, Hye-Nan KIM, Young-Min HAN, Dae-Seop SHIN
-
Publication number: 20090239955Abstract: Disclosed herein are novel obovatol derivatives represented by Chemical Formula 1, and pharmaceutically acceptable salts thereof. Having the ability to inhibit the growth of cancer cells and induce apoptosis in cancer cells, the derivatives or pharmaceutically acceptable salts thereof are useful in the prevention and treatment of cancer and in the suppression of cancer metastasis. Also, a method for preparing the derivatives, and pharmaceutical compositions comprising the derivatives as active ingredients are disclosed. wherein R1,R2 and R3 are as defined in the specification.Type: ApplicationFiled: July 28, 2008Publication date: September 24, 2009Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGYInventors: Byoung-Mog Kwon, Dong Cho Han, Su-Kyung Lee, Hye-Nan Kim, Young-Min Han, Dae-Seop Shin